Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2NET 1Gynecologic 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiosurgery 4Paclitaxel 4atezolizumab 3Nivolumab 3selpercatinib 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Irinotecan 2Carboplatin 2vandetanib 1taxane 1sargramostim 1romidepsin 1repotrectinib 1pralsetinib 1pentetreotide 1niraparib 1liposomal doxorubicin 1dostarlimab 1aldesleukin 1Vinorelbine 1Topotecan 1Thalidomide 1Temozolomide 1Specimen Handling 1Rose Bengal 1Radiation 1RRx-001 1Quality of Life 1Proton Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × taxane × Endocrine × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡